These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36100804)

  • 1. Association between hyporesponsiveness to erythropoiesis-stimulating agents and risk of brain hemorrhage in patients undergoing hemodialysis: the Q-Cohort Study.
    Uchida Y; Nakano T; Kitamura H; Taniguchi M; Tsuruya K; Kitazono T
    Clin Exp Nephrol; 2023 Jan; 27(1):79-88. PubMed ID: 36100804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients.
    Rivara MB; Ikizler TA; Ellis CD; Mehrotra R; Himmelfarb J
    BMC Nephrol; 2015 Jun; 16():79. PubMed ID: 26045064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Not baseline but time-dependent erythropoiesis-stimulating agent responsiveness predicts cardiovascular disease in hemodialysis patients receiving epoetin beta pegol: A multicenter prospective PARAMOUNT-HD Study.
    Fujii H; Hamano T; Tsuchiya K; Kuragano T; Joki N; Tsuruya K; Honda H; Uemura Y; Nitta K;
    Int J Cardiol; 2023 Mar; 375():110-118. PubMed ID: 36592827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyporesponsiveness to erythropoiesis-stimulating agent as a prognostic factor in Japanese hemodialysis patients: the Q-Cohort study.
    Eriguchi R; Taniguchi M; Ninomiya T; Hirakata H; Fujimi S; Tsuruya K; Kitazono T
    J Nephrol; 2015 Apr; 28(2):217-25. PubMed ID: 25080399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships among the Dosage of Erythropoiesis-Stimulating Agents, Erythropoietin Resistance Index, and Mortality in Maintenance Hemodialysis Patients.
    Pan S; Zhao DL; Li P; Sun XF; Zhou JH; Song KK; Wang Y; Miao LN; Ni ZH; Lin HL; Liu FY; Li Y; He YN; Wang NS; Wang CL; Zhang AH; Chen MH; Yang XP; Deng YY; Shao FM; Fu SX; Fang JA; Cai GY; Chen XM
    Blood Purif; 2022; 51(2):171-181. PubMed ID: 34175850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
    Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
    Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
    Bae MN; Kim SH; Kim YO; Jin DC; Song HC; Choi EJ; Kim YL; Kim YS; Kang SW; Kim NH; Yang CW; Kim YK
    PLoS One; 2015; 10(11):e0143348. PubMed ID: 26588085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
    Kalantar-Zadeh K; Lee GH; Miller JE; Streja E; Jing J; Robertson JA; Kovesdy CP
    Am J Kidney Dis; 2009 May; 53(5):823-34. PubMed ID: 19339087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients.
    Rattanasompattikul M; Molnar MZ; Zaritsky JJ; Hatamizadeh P; Jing J; Norris KC; Kovesdy CP; Kalantar-Zadeh K
    Nephrol Dial Transplant; 2013 Jul; 28(7):1936-45. PubMed ID: 23045431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients.
    Okazaki M; Komatsu M; Kawaguchi H; Tsuchiya K; Nitta K
    Blood Purif; 2014; 37(2):106-12. PubMed ID: 24603656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of the erythropoiesis stimulating agent resistance index in incident hemodiafiltration and high-flux hemodialysis patients.
    Marcelli D; Bayh I; Merello JI; Ponce P; Heaton A; Kircelli F; Chazot C; Di Benedetto A; Marelli C; Ladanyi E; Kroczak M; Stuard S; Grassmann A; Scatizzi L; Brand K; Canaud B
    Kidney Int; 2016 Jul; 90(1):192-202. PubMed ID: 27178833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin Hyporesponsiveness in Dialysis Patients: Possible Role of Statins.
    Hasegawa T; Zhao J; Fuller DS; Bieber B; Zee J; Morgenstern H; Hanafusa N; Nangaku M
    Am J Nephrol; 2017; 46(1):11-17. PubMed ID: 28564644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to Erythropoiesis-Stimulating Agents in Pre-Dialysis and Post-Dialysis Mortality in Japanese Incident Hemodialysis Patients.
    Hayashi T; Joki N; Tanaka Y; Iwasaki M; Kubo S; Matsukane A; Takahashi Y; Imamura Y; Hirahata K; Hase H
    Blood Purif; 2019; 47 Suppl 2(Suppl 1):31-37. PubMed ID: 30943479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient.
    Goodkin DA; Zhao J; Cases A; Nangaku M; Karaboyas A
    Am J Nephrol; 2022; 53(5):333-342. PubMed ID: 35462377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minor Elevation in C-Reactive Protein Levels Predicts Incidence of Erythropoiesis-Stimulating Agent Hyporesponsiveness among Hemodialysis Patients.
    Kimachi M; Fukuma S; Yamazaki S; Yamamoto Y; Akizawa T; Akiba T; Saito A; Fukuhara S
    Nephron; 2015; 131(2):123-30. PubMed ID: 26344924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between anti-erythropoietin receptor autoantibodies and responsiveness to erythropoiesis-stimulating agents in patients on hemodialysis: a multi-center cross-sectional study.
    Hara A; Koshino Y; Kurokawa Y; Shinozaki Y; Miyake T; Kitajima S; Toyama T; Iwata Y; Sakai N; Shimizu M; Furuichi K; Nakamura H; Wada T
    Clin Exp Nephrol; 2020 Jan; 24(1):88-95. PubMed ID: 31502102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influencing factors of the erythropoietin resistance index and its association with all-cause mortality in maintenance hemodialysis patients.
    Zhao X; Gan L; Hou FF; Liang X; Chen X; Chen Y; Ni Z; Zuo L
    Ren Fail; 2024 Dec; 46(1):2290922. PubMed ID: 38234178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic deterioration of prognosis associated with decreased grip strength and hyporesponse to erythropoiesis-stimulating agents in patients undergoing hemodialysis.
    Kobayashi S; Tanaka K; Hoshino J; Hara S; Kushiyama A; Tanaka Y; Motonishi S; Sakai K; Ozawa T
    Ren Fail; 2022 Dec; 44(1):1801-1810. PubMed ID: 36305202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin Resistance Index and the Affecting Factors in Children with Peritoneal Dialysis.
    Pınarbaşı AS; Dursun I; Günay N; Baatar B; Yel S; Dursun J; Balaban AG; Poyrazoğlu MH; Düşünsel R
    Blood Purif; 2021; 50(6):942-951. PubMed ID: 33784664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton Pump Inhibitors and Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Hemodialysis Patients: Results from the Japan Dialysis Outcomes and Practice Patterns Study.
    Nakashima A; Miyawaki Y; Komaba H; Kurita N; Onishi Y; Yokoo T; Fukagawa M
    Am J Nephrol; 2024; 55(2):165-174. PubMed ID: 37935135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.